Treatment For Feline Leukemia (FeLV) And Immunodeficiency Virus (FIV) Receives License Renewal From USDA

T-Cyte Therapeutics, Inc. announced their conditional license renewal from the United States Department of Agriculture for Lymphocyte T-Cell Immunomodulator (LTCI). LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV). LTCI is licensed and distributed by IMULAN BioTherapeutics; a US based veterinary immunobiology company. Conditional licenses are granted by the USDA for products which have passed safety and purity testing and where there is an emergency need or no other product available. LTCI is undergoing additional efficacy and potency studies.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards